{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:23:59Z","timestamp":1788186239668,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020707","name":"Janssen Pharmaceutical K.K","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020707","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Worldwide, prostate cancer (PC) is the second most diagnosed cancer and the fifth leading cause of cancer death in men. Hormonal therapies, commonly used for PC, are associated with a range of treatment-emergent adverse events (TEAEs). The population from Japan seems to be at higher risk of developing TEAEs of skin rash compared to the overall global population. This study was conducted to get a better insight into the incidence, management, and risk factors for skin rash during active treatment for advanced PC in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort of PC patients was identified and subsequently categorized, into non-metastatic and metastatic castration-resistant prostate cancer patients (nmCRPC and mCRPC), and metastatic castration-na\u00efve prostate cancer patients (mCNPC). The analysis was based on a dataset from the Medical Data Vision (MDV) database. Descriptive statistics were determined, and a multivariate Cox proportional hazards model was used to the associated risk factors for the onset of rash.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 1,738 nmCRPC patients, 630 mCRPC patients, and 454 mCNPC patients were included in this analysis. The median age was 78\u00a0years old and similar across the three cohorts. The skin rash incidence was 19.97% for nmCRPC cohort, 28.89% for mCRPC cohort, and 28.85% for mCNPC cohort. The median duration of skin rash ranged from 29 to 42\u00a0days. Statistically significant risk factors for developing skin rash included a history of allergy or hypersensitivity (all cohorts), increased age (nmCRPC and mCRPC), a body mass index (BMI) of\u2009&lt;\u200918.5 (nmCRPC and mCRPC), and a PSA level higher than the median (nmCRPC). Skin rash was commonly managed with systemic and topical corticosteroids which ranged from 41.76% to 67.03% for all cohorts. Antihistamines were infrequently used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study provides a better understanding of the real-world incidence, onset, duration, management and risk factors of skin rash in patients on active PC treatment in Japan. It was observed that approximately 20\u201330% of PC patients experience skin rash. Development of skin rash was associated with previous allergy or hypersensitivity, BMI of\u2009&lt;\u200918.5, increased age and higher PSA levels, and was usually treated with corticosteroids.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-023-01246-1","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T19:02:19Z","timestamp":1682708539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan"],"prefix":"10.1186","volume":"23","author":[{"given":"Raf","family":"De Moor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Koroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Bin-Chia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Young","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"6","key":"1246_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1246_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","volume":"61","author":"MM Center","year":"2012","unstructured":"Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079\u201392.","journal-title":"Eur Urol"},{"issue":"1","key":"1246_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/iju.13441","volume":"25","author":"T Saika","year":"2018","unstructured":"Saika T, Miura N, Fukumoto T, Yanagihara Y, Miyauchi Y, Kikugawa T. Role of robot-assisted radical prostatectomy in locally advanced prostate cancer. Int J Urol. 2018;25(1):30\u20135.","journal-title":"Int J Urol"},{"issue":"4","key":"1246_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrurol.2014.42","volume":"11","author":"K Ito","year":"2014","unstructured":"Ito K. Prostate cancer in Asian men. Nat Rev Urol. 2014;11(4):197\u2013212.","journal-title":"Nat Rev Urol"},{"issue":"9","key":"1246_CR5","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/iju.13380","volume":"24","author":"Y Kakehi","year":"2017","unstructured":"Kakehi Y, Sugimoto M, Taoka R. Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol. 2017;24(9):648\u201366.","journal-title":"Int J Urol"},{"issue":"13","key":"1246_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1200\/JCO.2006.08.0572","volume":"25","author":"SJ Freedland","year":"2007","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25(13):1765\u201371.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1246_CR7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465\u201374.","journal-title":"N Engl J Med"},{"issue":"15","key":"1246_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408\u201318.","journal-title":"N Engl J Med"},{"issue":"6","key":"1246_CR9","doi-asserted-by":"publisher","first-page":"a35","DOI":"10.1101\/cshperspect.a030635","volume":"8","author":"S Sumanasuriya","year":"2018","unstructured":"Sumanasuriya S, De Bono J. Treatment of advanced prostate cancer: a review of current therapies and future promise. Cold Spring Harb Perspect Med. 2018;8(6):a35.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1246_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fonc.2019.00801","volume":"9","author":"MA Rice","year":"2019","unstructured":"Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9:801.","journal-title":"Front Oncol"},{"issue":"5","key":"1246_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825\u201336.","journal-title":"Eur Urol"},{"issue":"4","key":"1246_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/13696998.2019.1705313","volume":"23","author":"A Shah","year":"2020","unstructured":"Shah A, Shah R, Kebede N, Mohamed A, Botteman M, Waldeck R, Hussain A. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. J Med Econ. 2020;23(4):330\u201346.","journal-title":"J Med Econ"},{"issue":"1","key":"1246_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12894-020-00689-0","volume":"20","author":"H Uemura","year":"2020","unstructured":"Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A, Smith A, Uemura H. Skin rash following administration of apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol. 2020;20(1):139.","journal-title":"BMC Urol"},{"issue":"14","key":"1246_CR14","doi-asserted-by":"publisher","first-page":"adv00210","DOI":"10.2340\/00015555-3572","volume":"100","author":"A Ikoma","year":"2020","unstructured":"Ikoma A, Ebata T, Fukuda R, Takase Y, Taniguchi N, Takemura K, Vaglio J, Poncet M, LeClercq D. Prevalence of pruritus in the elderly with dementia: a multicenter survey of Japanese patients. Acta Derm Venereol. 2020;100(14):adv00210.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1246_CR15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/1346-8138.12217","volume":"40","author":"N Kimura","year":"2013","unstructured":"Kimura N, Nakagami G, Takehara K, Miura Y, Nakamura T, Kawashima M, Tsunemi Y, Sanada H. Prevalence of asteatosis and asteatotic eczema among elderly residents in facilities covered by long-term care insurance. J Dermatol. 2013;40(9):770\u20131.","journal-title":"J Dermatol"},{"issue":"Suppl 2","key":"1246_CR16","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1093\/geront\/gnw003","volume":"56","author":"U Blume-Peytavi","year":"2016","unstructured":"Blume-Peytavi U, Kottner J, Sterry W, Hodin MW, Griffiths TW, Watson RE, Hay RJ, Griffiths CE. Age-associated skin conditions and diseases: current perspectives and future options. Gerontologist. 2016;56(Suppl 2):S230-242.","journal-title":"Gerontologist"},{"issue":"7","key":"1246_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/iju.14568","volume":"28","author":"T Iguchi","year":"2021","unstructured":"Iguchi T, Kimura G, Fukasawa S, Suzuki H, Uemura H, Nishimura K, Matsumoto H, Yokomizo A, Armstrong AJ, Rosbrook B, et al. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: a subgroup analysis of the phase III ARCHES study. Int J Urol. 2021;28(7):765\u201373.","journal-title":"Int J Urol"},{"issue":"Suppl","key":"1246_CR18","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.clml.2015.02.008","volume":"15","author":"SM Tinsley","year":"2015","unstructured":"Tinsley SM, Kurtin SE, Ridgeway JA. Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S64-69.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"1246_CR19","doi-asserted-by":"publisher","first-page":"937","DOI":"10.7150\/ijms.22224","volume":"15","author":"T Sakaeda","year":"2018","unstructured":"Sakaeda T, Kobuchi S, Yoshioka R, Haruna M, Takahata N, Ito Y, Sugano A, Fukuzawa K, Hayase T, Hayakawa T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018;15(9):937\u201343.","journal-title":"Int J Med Sci"},{"key":"1246_CR20","doi-asserted-by":"crossref","unstructured":"Tohi Y, Kato T, Fukuhara H, Kobayashi K, Ohira S, Ikeda K, Daizumoto K, Katayama S, Shimizu R, Nishimura K et al. Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium. Int J Clin Oncol (2022)","DOI":"10.1007\/s10147-022-02183-z"},{"key":"1246_CR21","unstructured":"About MDV Database. https:\/\/en.mdv.co.jp\/about-mdv-database\/. Accessed 23 Aug 2022."},{"key":"1246_CR22","doi-asserted-by":"crossref","unstructured":"ICD-10. International statistical classification of diseases and related health problems. 5th ed. World Health Organization; 2016","DOI":"10.1071\/SH17086"},{"issue":"1","key":"1246_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/aja.2008.19","volume":"11","author":"N Borley","year":"2009","unstructured":"Borley N, Feneley MR. Prostate cancer: diagnosis and staging. Asian J Androl. 2009;11(1):74\u201380.","journal-title":"Asian J Androl"},{"key":"1246_CR24","unstructured":"European Medicines Agency (EMA). Guideline on the evaluation of anticancer medicinal products in man. https:\/\/www.ema.europa.eu\/en\/evaluation-anticancer-medicinal-products-man. Accessed 24 Nov 2021."},{"issue":"1","key":"1246_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1021\/acs.chemrestox.9b00247","volume":"33","author":"C Ji","year":"2020","unstructured":"Ji C, Guha M, Zhu X, Whritenour J, Hemkens M, Tse S, Walker GS, Evans E, Khan NK, Finkelstein MB, Callegari E, Obach RS. Enzalutamide and apalutamide: in vitro chemical reactivity studies and activity in a mouse drug allergy model. Chem Res Toxicol. 2020;33(1):211\u201322. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00247.","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"1246_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5415\/apallergy.2016.6.3.149","volume":"6","author":"LK Tanno","year":"2016","unstructured":"Tanno LK, Calderon M, Demoly P. Joint Allergy Academies. Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11. Asia Pac Allergy. 2016;6(3):149\u201356.","journal-title":"Asia Pac Allergy"},{"issue":"2","key":"1246_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12055-020-01108-7","volume":"37","author":"SV Deo","year":"2021","unstructured":"Deo SV, Deo V, Sundaram V. Survival analysis-part 2: Cox proportional hazards model. Indian J Thorac Cardiovasc Surg. 2021;37(2):229\u201333.","journal-title":"Indian J Thorac Cardiovasc Surg"},{"key":"1246_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10: 811044.","journal-title":"Front Public Health"},{"key":"1246_CR29","unstructured":"U.S. Food & Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203415s014lbl.pdf. Accessed 23 Sep 2022."},{"issue":"1","key":"1246_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Ju\u00e1rez Soto \u00c1, Merseburger AS, \u00d6zg\u00fcro\u011flu M, Uemura H, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324.","journal-title":"N Engl J Med"},{"issue":"8","key":"1246_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1442-2042.2005.01121.x","volume":"12","author":"T Kobayashi","year":"2005","unstructured":"Kobayashi T, Kinoshita H, Nishizawa K, Mitsumori K, Ogawa O, Kamoto T. Age-associated increase of prostate-specific antigen in a high level of men visiting urological clinics. Int J Urol. 2005;12(8):733\u20138.","journal-title":"Int J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-023-01246-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01246-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T19:04:07Z","timestamp":1682708647000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-023-01246-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1246"],"URL":"https:\/\/doi.org\/10.1186\/s12894-023-01246-1","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"30 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this study, we used anonymized, data obtained from Japan Medical Data Vision Co., Ltd. Approval by an institutional review board and informed consent do not apply to the use of de-identified secondary data according to the Japanese ethical guidelines for medical and biological research involving human subjects (). To access the de-identified data, a license fee was paid to Japan Medical Data Vision Co., Ltd. All data processing was in compliance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mikiko Tohyama: received consulting fees from Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Ono Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Maruho Co.,Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Eli Lilly Japan K.K., Nobelpharma Co., Ltd., Janssen Pharmaceutical K.K. Raf De Moor: employee of Janssen Pharmaceutical K.K. and holds stock in Johnson & Johnson. Yosuke Koroki: employee of Janssen Pharmaceutical K.K. and holds stock in Johnson & Johnson. David Bin-Chia Wu: received grant from Pfizer; employee of Janssen Asia Pacific and holds stock in Johnson & Johnson. Dae Young Yu: employee of Janssen Asia Pacific. Chikara Ohyama: payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co.,Ltd., Bayer Yakuhin, Ltd., Nippon Shinyaku Co., Ltd., AstraZeneca K.K., Sanofi K.K; Support for attending meetings and\/or travel: Janssen Pharmaceutical K.K.; Participation on a Data Safety Monitoring Board or Advisory Board: Janssen Pharmaceutical K.K., Sanofi K.K.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}